ERBB2 and sarcoma: Moreover, a phase I/II clinical study in 19 patients with recurrent/refractory human epidermal growth factor receptor 2 (HER2)-positive sarcoma showed that injections were well tolerated in the lack of no dose-limiting toxicity [95].